Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation

摘要: In order to induce a therapeutic immunomodulatory activity, 11 patients with high-grade non-Hodgkin's lymphoma (HG-NHL) at median of 42 days after autologous bone marrow transplantation (ABMT) received recombinant interleukin-2 (rIL-2) subcutaneously dose 2 international megaunits (IMU)/m every other day for weeks and then 3 IMU/m twice week 1 year. Immunological studies, including T natural killer (NK) cell subset assessment, together functional assay, such as NK CD16-mediated cytotoxic activities, were performed before therapy, monthly. Phenotypic analyses showed significant persistant (P = 0.001) increase in the proportion absolute number total lymphocytes and, particularly both CD16 CD56 cells, from pre-treatment values 14 18% 30 38% respectively, recorded 6 months therapy. No changes observed CD25 (p55)-positive while 13 33% (after months) was CD122-positive cells. Furthermore, rIL-2 administration led an enhancement activity even lowest effector :target ratio activity. Clinical tolerance acceptable moderate fever fluid retention only onset treatment. None have progressed follow-up 22 (range 10-42 starting addition, two residual disease ABMT, one liver second lymph nodes, obtained complete response 10 7 respectively. These preliminary data suggest that infusion low-dose s.c. ABMT is safe well tolerated can selectively function. Additional are needed assess impact these immunological on relapse-free survival HG-NHL.